Matthew Wood

Matthew Wood F.Med.Sci. is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford. He directs the Laboratory of RNA biology and Neuromuscular Disease investigating development of RNA-based medicines for neuromuscular disease focusing on the development of advanced generation antisense oligonucleotides for Duchenne muscular dystrophy and related neuromuscular conditions. He is currently Director of MDUK Oxford Neuromuscular Centre and Director of the Oxford Harrington Rare Disease Centre.

He has pioneered the development of novel drug delivery systems including peptide and exosome-based technologies for the targeted delivery of macromolecular biologics, including oligonucleotides, to tissues including the brain. He is a co-founder of the biotech spin-outs Evox Therapeutics, PepGen, Orfonyx Bio and ISOgenix, and has recently led a major UK national initiative to establish a UK Nucleic Acid Therapy Accelerator (NATA).

Matthew is an advisor to numerous research funding agencies including UKRI, to Genomics England and to industry. In his role as Deputy Head of the Medical Sciences Division of the University of Oxford, Matthew leads strategic coordination of all innovation related activities. He currently serves as a Non-Executive Director of the University of Oxford’s technology transfer organisation, Oxford University Innovation (OUI).